Lexicon Pharmaceuticals, Inc. (LXRX) Earnings History
Net Loss27 years of earnings data (1999–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Lexicon Pharmaceuticals, Inc. (LXRX) Earnings Overview
As of June 23, 2026, Lexicon Pharmaceuticals, Inc. (LXRX) reported trailing twelve-month net income of -$26M, reflecting +77.8% year-over-year growth. The company earned $-0.07 per diluted share over the past four quarters, with a net profit margin of -101.1%.
Looking at the long-term picture, LXRX's historical earnings data spans multiple years. The company achieved its highest annual net income of $130M in fiscal 2019.
Lexicon Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARDX (-$58M net income, -15.1% margin), CORT ($48M net income, 13.1% margin), INVA ($504M net income, 63.8% margin), LXRX has room to improve margins relative to the peer group. Compare LXRX vs ARDX →
LXRX Earnings vs Peers
Earnings metrics vs comparable public companies
LXRX Historical Earnings Data (1999–2025)
27 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$50M | +74.9% | -$49M | $-0.14 | -101.1% | -98.2% |
| 2024 | -$200M | -13.1% | -$197M | $-0.63 | -644.8% | -634.2% |
| 2023 | -$177M | -73.7% | -$172M | $-0.80 | -14710.9% | -14265.0% |
| 2022 | -$102M | -16.2% | -$101M | $-0.62 | -73341.0% | -72489.2% |
| 2021 | -$88M | -49.8% | -$87M | $-0.61 | -29449.0% | -29224.8% |
| 2020 | -$59M | -145.0% | -$48M | $-0.63 | -244.1% | -199.2% |
| 2019 | $130M | +208.0% | $141M | $1.11 | 40.4% | 43.9% |
| 2018 | -$121M | +6.6% | -$103M | $-1.14 | -190.7% | -163.4% |
| 2017 | -$129M | +8.8% | -$137M | $-1.23 | -142.9% | -151.3% |
| 2016 | -$141M | -2920.7% | -$137M | $-1.36 | -169.7% | -164.6% |
| 2015 | -$5M | +95.3% | $1M | $-0.05 | -3.6% | 1.1% |
| 2014 | -$100M | +3.7% | -$100M | $-1.31 | -438.8% | -439.2% |
| 2013 | -$104M | +5.5% | -$102M | $-1.42 | -4686.1% | -4607.2% |
| 2012 | -$110M | +5.2% | -$108M | $-1.58 | -10120.4% | -9955.5% |
| 2011 | -$116M | -14.2% | -$114M | $-2.39 | -6285.3% | -6170.6% |
| 2010 | -$102M | -22.9% | -$96M | $-2.35 | -2073.7% | -1950.2% |
| 2009 | -$83M | -7.7% | -$90M | $-3.98 | -773.6% | -840.7% |
| 2008 | -$77M | -30.7% | -$97M | $-3.93 | -237.8% | -298.7% |
| 2007 | -$59M | -8.3% | -$75M | $-4.12 | -117.3% | -149.6% |
| 2006 | -$54M | -49.6% | -$55M | $-5.68 | -74.6% | -75.9% |
| 2005 | -$36M | +23.0% | -$36M | $-3.97 | -48.0% | -47.7% |
| 2004 | -$47M | +26.5% | -$47M | $-5.21 | -76.4% | -76.9% |
| 2003 | -$64M | -7.6% | -$63M | $-7.91 | -149.9% | -146.1% |
| 2002 | -$60M | -69.7% | -$63M | $-7.99 | -169.5% | -178.7% |
| 2001 | -$35M | -35.3% | -$44M | $-4.90 | -11.5% | -14.3% |
| 2000 | -$26M | -108.0% | -$35M | $-4.37 | -179.8% | -245.4% |
| 1999 | -$13M | - | -$13M | $-3.57 | -266.0% | -272.3% |
Download Data
Export LXRX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
27+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LXRX — Frequently Asked Questions
Quick answers to the most common questions about buying LXRX stock.
What is LXRX earnings per share (EPS)?
LXRX trailing twelve-month (TTM) diluted EPS is $-0.07, reflecting +77.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1999 to 2025 is available in the table on this page.
What is Lexicon Pharmaceuticals, Inc.'s net income?
Lexicon Pharmaceuticals, Inc. (LXRX) trailing twelve-month net income is $-26M as of 2025. Earnings grew +77.8% year-over-year.
Is LXRX profitable?
LXRX is not currently profitable on a TTM basis, reporting a net loss of $-26M. Net margin is -101.1%. Investors should monitor for a return to profitability.
What is LXRX's earnings growth rate?
LXRX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1999 to 2025.
What are LXRX's profit margins?
Lexicon Pharmaceuticals, Inc. net profit margin is -101.1%, operating margin is -98.2%, and gross margin is +99.4%. Below-average margins reflect competitive or cost pressures. Return on Equity is -39.7%.
Is LXRX growing earnings?
Yes, LXRX earnings are accelerating — EPS growth of +77.8% exceeds the 5-year CAGR of N/A. TTM net income reached $-26M. Earnings momentum is strengthening.
What was LXRX's best earnings year?
Lexicon Pharmaceuticals, Inc.'s highest annual net income on record is $130M, achieved in fiscal year 2019. Earnings history on this page spans 1999 to 2025 and includes all annual and quarterly figures.
What were LXRX's earnings last quarter?
LXRX's most recent reported quarter was Q1 2026. Net income was $-1M with diluted EPS of $-0.00. For a full breakdown of all quarters, see the quarterly earnings table on this page.